Company news
Ascendis Pharma A/s (NASDAQ:ASND) news
Every Ascendis Pharma A/s press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026
August 25, 2026
Ascendis Pharma Reports Second Quarter 2026 Financial Results
August 13, 2026
Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivo...
June 30, 2026
Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®
June 26, 2026
Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026
June 25, 2026
Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
June 13, 2026
Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026
June 8, 2026
Ascendis Pharma Reports First Quarter 2026 Financial Results
May 7, 2026
New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Ac...
May 6, 2026
Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026
April 30, 2026
Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028
April 21, 2026
Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq
April 20, 2026
Ascendis Pharma to List Ordinary Shares Directly on Nasdaq
April 8, 2026
Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States
April 6, 2026
New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropi...
March 17, 2026
New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia S...
March 16, 2026
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference
March 2, 2026
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older
February 27, 2026
Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results
February 11, 2026
Pendopharm Announces the Approval of Yorvipath® (palopegteriparatide injection) for the Treatment of Chronic Hypoparathyroidism in Adults
February 6, 2026
Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026
February 4, 2026
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference
January 9, 2026
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)
January 8, 2026
Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia
November 25, 2025
Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics
November 17, 2025
Ascendis Pharma Reports Third Quarter 2025 Financial Results
November 12, 2025
New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatid...
November 7, 2025
Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025
November 5, 2025
3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025
November 3, 2025
Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Ac...
October 8, 2025
Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025
September 2, 2025
Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference
August 28, 2025
Ascendis Pharma Reports Second Quarter 2025 Financial Results
August 7, 2025
Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025
July 31, 2025
FDA Approves SKYTROFA® (Lonapegsomatropin-tcgd) for the Once-Weekly Treatment of Adults with Growth Hormone Deficiency
July 28, 2025
New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, In...
July 14, 2025
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025
July 7, 2025
TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COAC...
June 9, 2025
FDA Accepts TransCon® CNP NDA for Priority Review
June 2, 2025
New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)
May 13, 2025
New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism
May 12, 2025
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE & ESE 2025
May 5, 2025
Ascendis Pharma Reports First Quarter 2025 Financial Results
May 1, 2025
Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia
March 31, 2025
FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA
February 20, 2025
Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs
February 12, 2025
YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults
December 19, 2024
FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormon...
December 12, 2024